Akt Activation With <scp>IPL344</scp> Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open‐Label Study
These preliminary data indicate that IPL344 was safe and well-tolerated, and possibly effective. Our findings may merit further investigation in a larger placebo-controlled clinical trial.
Authors
- Jeremy M. Shefner (ORCID: https://orcid.org/0000-0001-5067-5602)
- Irun R. Cohen (ORCID: https://orcid.org/0000-0002-3906-6993)
- Marc Gotkine (ORCID: https://orcid.org/0000-0003-2541-6232)
- David Schoenfeld (ORCID: https://orcid.org/0000-0003-1948-3711)
- Merit Cudkowicz (ORCID: https://orcid.org/0000-0002-7075-1681)
- Yossef Lerner
- Colin Klein
- Ilana Cohen
- Eran Ovadia
Institutions
- Barrow Neurological Institute (US)
- Harvard University (US)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Meir Medical Center (IL)
- Massachusetts General Hospital (US)
- Mapi Pharma (Israel) (IL)
- Weizmann Institute of Science (IL)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1002/mus.28393
- Citations
- 2
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 2.78